Risk Evaluation and Mitigation Strategies: An Update
The FDA’s new strategy to ensure that the safety of certain drugs outweighs the risks they potentially pose to patients continues to evolve as the healthcare industry takes an active role in current and future REMS requirements.
Reimbursement FAQs: Date of Service Billing, Billing Codes, Least Costly Alternatives and More
Examining issues regarding SCIG billing, coding and Medicare claims, along with questions about certification of homebound patients and products with new reimbursement codes.
ACOS: Reducing Costs While Improving Quality of Care
With the push to reduce the cost of healthcare yet improve the quality and efficiency of care, Accountable Care Organizations could be a solution.
Reimbursement FAQs: IVIG vs SCIG, Medicare Benefits and More
We’re answering questions about switching from intravenous immune globulin therapy to subcutaneous immune globulin therapy, copayment for self-injectables, the definition of homebound patients and more.
Reimbursement FAQs: Coding System Updates and Other News
Discussing reimbursement codes and insurance coverage of Fluzone and off-label uses for Rituxan.